Ham S, Harrison C, de Kretser D, et al. - This research was sought to compare the impacts of activins on normal and keloid‐derived human dermal fibroblasts and evaluated a novel treatment for keloids using follistatin. Researchers applied normal skin and keloid tissue samples from 11 patients to develop primary fibroblast cultures, which were correlated in terms of their histology and relevant gene and protein expression. This study’s findings demonstrate that activator protein 1 inhibitor significantly reduced INHBA and connective tissue growth factor (CTGF) expression in keloid fibroblasts and a single treatment of follistatin over 5 days significantly inhibited activin and various matrix‐related genes in keloid fibroblasts when compared to controls. The data indicated that Follistatin, by binding activin A, suppressed CTGF expression implying a novel therapeutic role in managing keloids and perhaps other fibrotic diseases.